Glucocorticoids in the treatment of glomerular diseases: Pitfalls and pearls

Clinical Journal of the American Society of Nephrology

Volumn 13, Issue 5, 2018, Pages 815-822

  Ponticelli, Claudio ^a,c   Locatelli, Francesco ^b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b A MANZONI HOSPITAL   (Italy)

^c Ospedale Manzoni ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CYTOCHROME P450; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; NEPHRIN; RIFAMPICIN; STEROID; TRANSCRIPTION FACTOR AP 1;

ACNE; ADRENAL INSUFFICIENCY; ANTIINFLAMMATORY ACTIVITY; ASEPTIC NECROSIS; ATROPHY; CATARACT; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG THERAPEUTIC INDEX; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; GROWTH RETARDATION; HIRSUTISM; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MOON FACE; MYOPATHY; PEPTIC ULCER; PODOCYTE; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; STRIA; TRANSACTIVATION; TREATMENT DURATION; DRUG EFFECT; GLOMERULONEPHRITIS; INBORN ERROR OF METABOLISM;

GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, IGA; GLOMERULONEPHRITIS, MEMBRANOUS; GLUCOCORTICOIDS; HUMANS; LUPUS NEPHRITIS; METABOLISM, INBORN ERRORS; PODOCYTES; RECEPTORS, GLUCOCORTICOID;

EID: 85046768605     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12991117     Document Type: Review

References (51)

1. Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ: Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 94: 1548–1554, 2009
2. Kirschke E, Goswami D, Southworth D, Griffin PR, Agard DA: Glucocorticoid receptor function regulated by coordinated action of the Hsp90 andHsp70 chaperone cycles. Cell 157: 1685– 1697, 2014
3. Kadmiel M, Cidlowski JA: Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 34: 518–530, 2013
4. Schäcke H, Schottelius A, Döcke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K: Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A 101: 227–232, 2004
5. Teeninga N, Kist-van Holthe JE, van den Akker EL, Kersten MC, Boersma E, Krabbe HG, Knoers NV, van der Heijden AJ, Koper JW, Nauta J: Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome. Kidney Int 85: 1444–1453, 2014
6. Dhandapani MC, Venkatesan V, Rengaswamy NB, Gowrishankar K, Nageswaran P, Perumal V: Association of ACE and MDR1 gene polymorphisms with steroid resistance in children with idiopathic nephrotic syndrome. Genet Test Mol Biomarkers 19: 454–456, 2015
7. Ramamoorthy S, Cidlowski JA: Corticosteroids: Mechanisms of action inhealthand disease. Rheum Dis ClinNorth Am 42: 15–31, vii, 2016
8. Guess A, Agrawal S, Wei CC, Ransom RF, Benndorf R, Smoyer WE: Dose- and time-dependent glucocorticoid receptor signaling in podocytes. Am J Physiol Renal Physiol 299: F845–F853, 2010
9. Ohashi T, Uchida K, Uchida S, Sasaki S, Nitta K: Dexamethasone increases the phosphorylation of nephrin in cultured podocytes. Clin Exp Nephrol 15: 688–693, 2011
10. Zhang J, Pippin JW, Krofft RD, Naito S, Liu ZH, Shankland SJ: Podocyte repopulation by renal progenitor cells following glucocorticoids treatment in experimental FSGS. Am J Physiol Renal Physiol 304: F1375–F1389, 2013
11. Lewko B, Waszkiewicz A, Maryn A, Gołos M, Latawiec E, Daca A, Witkowski JM, Angielski S, Stępinski J: Dexamethasone- dependent modulation of cyclic GMP synthesis in podocytes. Mol Cell Biochem 409: 243–253, 2015
12. Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, Sbardella E, Gianfrilli D, Pozza C, Pasqualetti P, Morrone S, Santoni A, Naro F, Colao A, Pivonello R, Lenzi A: Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): A single-blind, randomised controlled trial [published online ahead of print December 8, 2017]. Lancet Diabetes Endocrinol 10.1016/S2213-8587(17)30398-4
13. Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME: Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176: 238–246, 2016
14. Judd LL, Schettler PJ, Brown ES, Wolkowitz OM, Sternberg EM, Bender BG, Bulloch K, Cidlowski JA, de Kloet ER, Fardet L, Joëls M, Leung DY, McEwen BS, Roozendaal B, Van Rossum EF, Ahn J, Brown DW, Plitt A, Singh G: Adverse consequences of glucocorticoid medication: Psychological, cognitive, and behavioral effects. Am J Psychiatry 171: 1045–1051, 2014
15. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP: HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18: 601–607, 2005
16. Han SH, Park SY, Li JJ, Kwak SJ, Jung DS, Choi HY, Lee JE, Moon SJ, Kim DK, Han DS, Kang SW: Glomerular glucocorticoid receptor expression is reduced in late responders to steroids in adult-onset minimal changedisease. Nephrol Dial Transplant 23: 169–175, 2008
17. Kidney Disease Improving Global Outcomes (KDIGO): KDIGO clinical practice guideline for glomerulonephritis. Kidney Int 2 [Supplement 2]: 1–216, 2012
18. Vivarelli M, Massella L, Ruggiero B, Emma F: Minimal change disease. Clin J Am Soc Nephrol 12: 332–345, 2017
19. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N: Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney Int 72: 1429–1447, 2007
20. Ravani P, Bonanni A, Rossi R, Caridi G, Ghiggeri GM: Anti-CD20 antibodies for idiopathic nephrotic syndrome in children. Clin J Am Soc Nephrol 11: 710–720, 2016
21. Laurin LP, Gasim AM, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Foster BJ, Nachman PH: Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS. Clin J Am Soc Nephrol 11: 386–394, 2016
22. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, Ponticelli C, Locatelli F: Corticosteroid effectiveness in IgA nephropathy: Long-term results of a randomized, controlled trial. J Am Soc Nephrol 15: 157–163, 2004
23. Manno C, Torres DD, Rossini M, Pesce F, Schena FP: Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant 24: 3694–3701, 2009
24. Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R; VALIGA study of the ERA-EDTA Immunonephrology Working Group: Corticosteroids in IgA nephropathy: A retrospective analysis from the VALIGA study. J Am Soc Nephrol 26: 2248–2258, 2015
25. Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J; STOP-IgAN Investigators: Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373: 2225–2236, 2015
26. Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Wheeler D, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Wang HY, Perkovic V; TESTING Study Group: Effect of oral methylprednisolone on clinical outcomes in patientswith IgA nephropathy: The TESTING randomized clinical trial. JAMA 318: 432–442, 2017
27. Coppo R: Corticosteroids in IgA nephropathy: Lessons from recent studies. J Am Soc Nephrol 28: 25–33, 2017
28. Abdalla MI, Herfarth H: Budesonide for the treatment of ulcerative colitis. Expert Opin Pharmacother 17: 1549–1559, 2016
29. Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L; NEFIGAN Trial Investigators: Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389: 2117–2127, 2017
30. Lv J, Xu D, Perkovic V, Ma X, Johnson DW, Woodward M, Levin A, Zhang H, Wang H; TESTING Study Group: Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol 23: 1108–1116, 2012
31. Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, Molony DA, Schena FP, Strippoli GF: Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 8: CD003965, 2015
32. Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allegri L, Cirami L, Procaccini AD, Locatelli F: Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21: 1783–1790, 2010
33. Hogan SL, Muller KE, Jennette JC, Falk RJ: A review of therapeutic studies of idiopathic membranous glomerulopathy. Am J Kidney Dis 25: 862–875, 1995
34. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, Sasdelli M, Redaelli B, Grassi C, Pozzi C: A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 48: 1600– 1604, 1995
35. Jha V, Ganguli A, Saha TK, Kohli HS, Sud K, Gupta KL, Joshi K, Sakhuja V: A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18: 1899–1904, 2007
36. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF: Mycophenolate mofetil in idiopathic membranous nephropathy: A clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 50: 248–256, 2007
37. Caro J, Gutiérrez-Solís E, Rojas-Rivera J, Agraz I, Ramos N, Rabasco C, Espinosa M, Valera A, Martín M, Frutos MÁ, Perea L, Juárez GF, Ocana J, Arroyo D, Goicoechea M, Fernández L, Oliet A, Hernández Y, Romera A, Segarra A, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Espanola de Nefrología (GLOSEN): Predictors of response and relapse in patients with idiopathic membranous nephropathy treatedwithtacrolimus. Nephrol Dial Transplant 30: 467–474, 2015
38. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasà M, Remuzzi G: Rituximab in idiopathic membranous nephropathy. J AmSoc Nephrol 23: 1416–1425, 2012
39. Sethi S, Fervenza FC: Membranoproliferative glomerulonephritis— A new look at an old entity. NEngl J Med 366: 1119–1131, 2012
40. Pickering MC, D’Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M, Doyle M, Fakhouri F, Fervenza FC, Fogo AB, Frémeaux-Bacchi V, Gale DP, Goicoechea de Jorge E, Griffin G, Harris CL, Holers VM, Johnson S, Lavin PJ, Medjeral-Thomas N, Paul Morgan B, Nast CC, Noel LH, Peters DK, Rodríguez de Córdoba S, Servais A, Sethi S, Song WC, Tamburini P, Thurman JM, Zavros M, Cook HT: C3 glomerulopathy: Consensus report. Kidney Int 84: 1079–1089, 2013
41. Rabasco C, Cavero T, Román E, Rojas-Rivera J, Olea T, Espinosa M, Cabello V, Fernández-Juarez G, González F, Ávila A, Baltar JM, Díaz M, Alegre R, Elías S, Antón M, Frutos MA, Pobes A, Blasco M, Martín F, Bernis C, Macías M, Barroso S, de Lorenzo A, Ariceta G, López-Mendoza M, Rivas B, López-Revuelta K, Campistol JM, Mendizábal S, de Córdoba SR, Praga M; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 88: 1153–1160, 2015
42. Nester CM, Smith RJ: Complement inhibitioninC3glomerulopathy. Semin Immunol 28: 241–249, 2016
43. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA: 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65: 1–11, 2013
44. Chen M, Kallenberg CG, Zhao MH: ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol 5: 313– 318, 2009
45. Moroni G, Ponticelli C: Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmun Rev 13: 723– 729, 2014
46. Manenti L, Urban ML, Maritati F, Galetti M, Vaglio A: Complement blockade in ANCA-associated vasculitis: An index case, current concepts and future perspectives. Intern Emerg Med 12: 727–731, 2017
47. Ponticelli C, Glassock RJ, Moroni G: Induction and maintenance therapy in proliferative lupus nephritis. J Nephrol 23: 9–16, 2010
48. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135: 248–257, 2001
49. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365: 1886–1895, 2011
50. Moroni G, Doria A, Mosca M, Alberighi OD, Ferraccioli G, Todesco S, Manno C, Altieri P, Ferrara R, Greco S, Ponticelli C: A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 1: 925–932, 2006
51. Mok CC: Calcineurin inhibitors in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 31: 429–438, 2017